MGMT and glioblastoma: A phase I trial (NCT01700569) demonstrated that the combination of TMZ, folic acid, as well as radiotherapy was feasible to promote MGMT methylation in patients with unmethylated MGMT.60 In addition, a preclinical study showed that bortezomib can strengthen the GBM’s sensitivity to TMZ by decreasing MGMT levels.61 These suggest that targeting MGMT induces TMZ sensitivity is very promising.